1. A comparative studies of the effects of Varidase and Urokinase on the experimental hyphema produced by the injection of rabbits auto-blood were performed in 20 eyes. 2. Subconjunctival injection of each enzymes were perfomed 1 hour after production of hyphema, and thereafter repeated once daily for 10 days. 3. Varidase increased the rate of absorption of hyphema, but Urokinase had no effect. 4. No side reactions were observed following the subconjunctival injection of these enzymes.
Absorption* ; Hyphema* ; Rabbits* ; Streptodornase and Streptokinase ; Urokinase-Type Plasminogen Activator

A Case of Eales' disease in a 36 years, old R.O.K. officer, male, is presented in this report. This patient has been suffered from Eales' disease for these 3 years. Although the recovery from this disease was occurred two times previously, it was resulted as Complete blindness of O. D. due to the Complications of this disease and poor visual acuity of O. S. on account of marked vitreous opacity and retinal hemorrhage in spite of intensive treatment with anti-tuber culous agents, steroids, varidase and subconjunctival injection of 3% Sodiumchloride solution.
Blindness ; Humans ; Male ; Retinal Hemorrhage ; Steroids ; Streptodornase and Streptokinase ; Visual Acuity

OBJECTIVE: In most cases, the postoperative course of a chronic subdural hematoma (CSDH) is good, but CSDHs sometimes remain after the inserted catheter is removed, and the outcomes of such remnant hematomas are unclear. As oral streptokinase-streptodornase (OSS) has anti-inflammatory and hematologic effects, we assessed the effects of OSS on remnant CSDHs through a retrospective analysis of clinical data. METHODS: This study included 101 patients with traumatic CSDH who had remnant CSDH after burr-hole trephination with the closed drainage system between October 2009 and December 2012. We assessed the clinical outcomes, remnant CSDH volume, and recurrence rate from computed tomography scans in order to evaluate the effects of OSS. RESULTS: No significant differences were found in the changes in remnant hematoma volume between the OSS-treated and non-treated groups (p=0.531). The reoperation rate because of was 5.4% (2 patients) in the OSS-treated group and 6.3% (4 patients) in the non-treated group. The number of patients requiring reoperation did not differ between the groups (p=0.658). CONCLUSION: OSS treatment was not associated with a significant reduction in the remnant CSDH volume or recurrence rate after burr-hole drainage. Thus, there seems to be no basis for using OSS in CSDH patients.
Catheters ; Drainage ; Hematoma ; Hematoma, Subdural, Chronic* ; Humans ; Recurrence ; Reoperation ; Retrospective Studies ; Streptodornase and Streptokinase ; Trephining